A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
作者:
主题词
老年人(Aged);心血管疾病(Cardiovascular Diseases);糖尿病, 2型(Diabetes Mellitus, Type 2);二肽基肽酶Ⅳ抑制剂(Dipeptidyl-Peptidase IV Inhibitors);双盲法(Double-Blind Method);用药计划表(Drug Administration Schedule);女(雌)性(Female);随访研究(Follow-Up Studies);杂环化合物, 2环(Heterocyclic Compounds, 2-Ring);人类(Humans);降血糖药(Hypoglycemic Agents);男(雄)性(Male);中年人(Middle Aged);吡喃类(Pyrans);危险因素(Risk Factors)
DOI
10.1186/s12933-017-0593-8
PMID
28893244
发布时间
2024-06-03
- 浏览9
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文